Clinical trials: Human Immunodeficiency Virus Type 1
HIV Infection
An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.
The primary objective of the TMC114-C215 study is to evaluate the safety and tolerability of TMC114/RTV over time. The secondary objectives are to evaluate the antiviral activity over time and to evaluate the immunological effect…
- Trial name
- NCT00081588
- Testing
- TMC114
- Where
- 64 sites in United States, Argentina and 11 more
- Volunteers
- 555 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV
A Study to Assess Safety and Immunogenicity of Conserved Mosaic HIV-1 Vaccines
The object of the study is to assess the safety profile of candidate vaccines ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVcnsv4 administered sequentially in healthy HIV-1/2 negative adult volunteers.
- Trial name
- NCT04586673
- Testing
- ChAdOx1.tHIVconsv1 (C1), MVA.tHIVconsv3 (M3), MVA.tHIVconsv4 (M4)
- Where
- United Kingdom
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Oxford
HIV-1 Infection
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
This study was done to look at a method of hormonal birth control, called the NuvaRing, and specific anti-HIV medications, called antiretrovirals (ARVs).
- Trial name
- NCT01903031
- Testing
- Nuvaring, EFV, ATV/r
- Where
- 21 sites in United States, Botswana and 6 more
- Volunteers
- 84 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infections
"Prime-Boost" Vaccine Schedule for Prevention of HIV Infection
This study will determine the safety and side effects of two experimental HIV vaccines given in a "prime-boost" schedule. It will also monitor participants for the social impact of being in an HIV vaccine study (e.g., problems…
- Trial name
- NCT00109629
- Testing
- VRC-HIVDNA016-00-VP, VRC-HIVADV014-00
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
The hypothesis tested in this study is that doravirine (MK-1439) at the final dose selected is superior to efavirenz, each given in combination with TRUVADA®, as measured by the percentage of participants with CNS events by Week…
- Trial name
- NCT01632345
- Testing
- Doravirine, Efavirenz, TRUVADA®
- Volunteers
- 342 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infection
Phase I Study to Evaluate the Safety and Immunogenicity of HIV-1 Immunogen in Children With HIV-1 Infection
This is a single dose, phase I study to evaluate the safety/tolerance and the immunogenicity of HIV-1 Immunogen, gp120-depleted inactivated HIV-1 preparation in Incomplete Freund's Adjuvant (IFA), in children with HIV-1…
- Trial name
- NCT00001445
- Testing
- HIV-1 Immunogen
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
HIV-1, AIDS
HLA-B35 Alleles and AIDS
This study will identify variations in the genome of the human immunodeficiency virus (HIV) early after infection and following the development of AIDS.
- Trial name
- NCT00340223
- Where
- 7 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
HIV-1 Infection
Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera
The purpose of this research study is to evaluate how easy it is for female HIV- positive subjects taking Complera to comply with the dietary requirement using a food diary in the short term (4 weeks) and long term (24 weeks and…
- Trial name
- NCT01701895
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Prema Menezes, PhD, PA-C
Human Immunodeficiency Virus (HIV)
A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children
The purpose of the study is to assess the ability to swallow the Darunavir/Cobicistat (DRV/COBI) fixed dosed combination (FDC) tablet dispersed in water.
- Trial name
- NCT05197075
- Testing
- DRV/COBI FDC
- Where
- 6 sites in United States, South Africa and 1 more
- Volunteers
- 15 people
- Sponsor
- Janssen Research & Development, LLC
HIV/AIDS
Simplified Treatment of Anti-retrovirus in China (C-STAR)
To observe the efficacy and safety of simplified therapy regimen for treating with HIV-1 infected patients in Chinese real word.
- Trial name
- NCT03603977
- Testing
- Lpv/r+3TC
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Guangzhou 8th People's Hospital
HIV Infections
A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection
PRIMARY: To evaluate the safety, tolerability, and pharmacokinetics of daily oral thalidomide. SECONDARY: To examine the effect of thalidomide on antiviral activity and tumor necrosis factor-alpha (TNF-alpha) production, and the…
- Trial name
- NCT00000812
- Testing
- Thalidomide
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients
In HIV infected patients, individuals exposed to the virus of Hepatitis B are more susceptible to develop a chronic and severe liver disease with a major risk of cirrhosis and liver cancer.
- Trial name
- VIHVAC-B (NCT00480792)
- Testing
- GenHevac B Pasteur
- Where
- France
- Volunteers
- 437 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Study Evaluating Vaccine in Adults With HIV
The purpose of this study is to learn whether the study vaccine and adjuvants (drugs that are used to help improve immune responses) have an acceptable safety profile in treating individuals with HIV.
- Trial name
- NCT00195234
- Testing
- HIV CTL MEP 1000 micrograms, 19 months per subject
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
HIV, Hyperlipidemia
Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
The success of combination antiretroviral therapy heralded a revolution in the treatment of HIV in the mid-1990s. However, severe treatment-associated side effects have been observed including diabetes and increased cholesterol…
- Conditions
- HIV, Hyperlipidemia, Hypertriglyceridemia, HIV Infections
- Trial name
- NCT00887653
- Testing
- raltegravir
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- The Miriam Hospital
HIV Infections
Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults
The purpose of this study is to determine the safety of and immune response to two experimental vaccines, designed for use in combination, for the prevention of HIV infection in healthy adults.
- Trial name
- NCT00428337
- Testing
- EP-1233, MVA-mBN32
- Where
- 3 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
This is a randomized, double-blind, double-dummy, 48-week, comparative study. Approximately 150 HIV-infected, treatment-naïve patients with CCR5-tropic virus will be stratified by HIV-1 RNA: ≥100,000 copies/mL versus <100,000…
- Trial name
- NCT01338883
- Testing
- Cenicriviroc 100 mg, Cenicriviroc 200 mg + Truvada, Sustiva + Truvada
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 143 people
- Sponsor
- Tobira Therapeutics, Inc.
HIV Infections
Inflammation, NK Cells, Antisense Protein and Exosomes, and Correlation With Immune Response During HIV Infection
More than 90% of HIV-infected patients on antiretroviral therapy have an undetectable viral load. However, approximately 15% of these individuals do not sufficiently restore their TCD4 lymphocytes and have an unfavorable CD4/CD8…
- Trial name
- INKASE (NCT05243381)
- Testing
- 20 ml blood test
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Montpellier
HIV-1 Infection
Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication
Effect on HIV-1 cell reservoirs of the concomitant administration of intensive chemotherapy and the pharmacological blockade of CCR5 coreceptors: a pilot, open, randomized, and controlled clinical trial.
- Trial name
- CHEMOMAR (NCT02486510)
- Testing
- Maraviroc
- Where
- 2 sites in Spain
- Volunteers
- 7 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Human Immunodeficiency Virus Infection
A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.
This is a double-blind Phase 2a study to test the safety and efficacy of an investigational HIV drug, amdoxovir (300 mg or 500 mg twice daily) compared with tenofovir DF 300 mg once daily in HIV-1 infected antiretroviral…
- Trial name
- NCT01737359
- Testing
- amdoxovir 300 mg bid, amdoxovir 500 mg bid, tenofovir DF 300 mg qd
- Where
- 6 sites in Argentina
- Volunteers
- 2 people
- Sponsor
- RFS Pharma, LLC
Infection, Human Immunodeficiency Virus
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects
LAI115428 is a Phase I, randomized, repeat dose escalation study to determine the safety, tolerability, and PK profile of intramuscular and subcutaneous injections of GSK1265744 in a long acting parenteral (LAP) formulation in…
- Trial name
- NCT01593046
- Testing
- GSK1265744 Oral, GSK1265744 LAP 800mg intramuscular injection, GSK1265744 LAP 200mg subcutaneous injection
- Where
- 2 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.